Your GLP-1 Was Denied by Insurance: What to Do Next

How Bad Is the Denial Problem?

The numbers paint a clear picture of the current landscape. Insurance companies are approving fewer GLP-1 prescriptions, even as demand grows.

That 88% number is the one that matters most. The vast majority of people who are denied never challenge it. If you are in that group, the appeal process described below is the single highest-return action you can take. The odds favor you.

Understanding Why You Were Denied

The first step is reading your denial letter carefully. The specific reason matters because it determines your strategy. There are four common denial categories, and each has a different response.

"Not medically necessary" is the most common denial and the most winnable on appeal. It usually means the initial prior authorization did not include enough documentation to justify the prescription. A detailed physician letter often resolves it.

"Plan exclusion" is the hardest to overturn because the plan simply does not cover the medication category. In that case, skip directly to the alternative paths section below.

The Appeal Process: Step by Step

Step 1: Get your denial in writing

If you only received a verbal denial, request the written determination. You need the specific denial reason and the plan's appeal instructions, including the deadline. Most plans give you 30-60 days to file an internal appeal.

Step 2: Build your documentation package

This is where most appeals are won or lost. You need:

• BMI history showing a pattern of obesity over time, not just a single measurement
• Comorbidity documentation: diabetes, hypertension, cardiovascular disease, sleep apnea, PCOS, fatty liver disease, or joint problems related to weight
• Prior weight loss attempts: any diet programs, exercise plans, nutritionist visits, or previous medications tried. Include dates and outcomes
• Lab work: HbA1c, lipid panels, blood pressure readings that support the medical case
• Physician letter of medical necessity: this is the most important document. Ask your prescribing doctor to write a specific letter explaining why GLP-1 medication is appropriate for your case. Generic letters are less effective than detailed, personalized ones

Step 3: File the internal appeal

Submit everything within the deadline. Include a brief cover letter summarizing your case. Reference the specific clinical guidelines that support GLP-1 use for your condition. The American Gastroenterological Association and the Endocrine Society both have published guidelines recommending GLP-1 medications for patients who meet BMI and comorbidity criteria.

Step 4: Request a peer-to-peer review

This is often the fastest path to approval. Your prescribing doctor can request to speak directly with the insurance company's reviewing physician. In many cases, a 10-minute conversation between two doctors resolves what months of paperwork could not. Ask your doctor's office if they offer this.

Step 5: External review (if internal appeal fails)

If the internal appeal is denied, you have the right to an independent external review. An outside reviewer, not employed by your insurance company, evaluates your case. Nearly 40% of external reviews overturn the denial. This costs you nothing. The insurance company pays for the external review.

Alternative Paths to Coverage

If appealing the denial does not work, or if your plan categorically excludes weight loss medications, there are other routes.

Alternative indication prescribing

Wegovy® (semaglutide) is FDA-approved for cardiovascular risk reduction in addition to weight management. Zepbound® (tirzepatide) is approved for obstructive sleep apnea. If you have either of these conditions, your doctor may be able to prescribe the medication for the covered indication. The medication is the same. The covered diagnosis changes.

Similarly, Ozempic® (semaglutide for diabetes) and Mounjaro® (tirzepatide for diabetes) are covered by most plans when prescribed for type 2 diabetes. If you have diabetes in addition to obesity, the diabetes-indicated version may be covered.

Manufacturer savings programs

If you have commercial insurance that covers the medication but your copay is high, manufacturer savings cards can bring it down:

• Wegovy and Zepbound savings cards: both can bring your copay as low as $25/month if you have qualifying commercial insurance

These savings cards do not apply to Medicare, Medicaid, or government-funded plans, and they will not help if your plan excludes the medication entirely.

State insurance commissioner complaint

If you believe your denial was improper (for example, if the plan covers the medication for some patients but denied you without adequate review), you can file a complaint with your state's department of insurance. This is free and sometimes prompts a faster resolution than the internal appeal process.

Open enrollment switch

If your current plan does not cover GLP-1 medications at all, check during open enrollment whether other plans offered through your employer or the marketplace include coverage. Some plans explicitly list GLP-1 medications on their formularies. Call the plan before enrolling and ask specifically about coverage for the medication by name.

Going Around Insurance: Cash-Pay Pricing

If insurance is not going to work, paying directly removes the insurer from the equation. The prices are well below list price thanks to manufacturer programs and telehealth competition.

The Wegovy pill's starter dose at $149/month is currently the most affordable entry point for any FDA-approved GLP-1 weight loss medication. NovoCare's introductory 4mg price ($149) expires April 15, 2026, after which it moves to $199/month. The 1.5mg starter remains at $149.

Compounded medications are a lower-cost option, but they are not FDA-approved and face increasing regulatory scrutiny as the FDA has declared GLP-1 shortages resolved. If you go this route, verify your provider works with licensed pharmacies and requires a prescription from a licensed clinician. See our compounded GLP-1 safety guide for what to look for.

For a breakdown of what different program types include (medication-only vs. programs with labs, coaching, and monitoring), see our GLP-1 program costs guide.

HSA and FSA eligibility

GLP-1 medications prescribed for weight loss by a licensed provider are generally eligible for HSA (Health Savings Account) and FSA (Flexible Spending Account) reimbursement. This applies to both brand-name and compounded versions as long as you have a valid prescription. Check with your HSA/FSA administrator for specific rules, as some require a letter of medical necessity.

The Bottom Line

Getting denied for a GLP-1 prescription is frustrating, but it is not the end of the road. If your denial is for "not medically necessary" or "incomplete step therapy," the appeal process works in your favor more often than not. Start with a physician letter of medical necessity, put your documentation together, and file the appeal.

If your plan categorically excludes weight loss medications, talk to your doctor about alternative indications. You can also look at other plans during open enrollment or go the manufacturer cash-pay route to bypass insurance entirely.

The 88% of patients who never appeal are leaving access on the table. The data says most of them would win.

Featured Programs with Clinician Support

These programs include licensed clinician consultations and structured support. Compare what's included before deciding.

Sources

1. GoodRx. Tracking insurance coverage for GLP-1 agonists. Updated 2026.
2. PMC. Coverage and prior authorization policies for semaglutide and tirzepatide.
3. AJMC. Rising costs lead insurers to drop weight loss drug coverage.
4. Medical Economics. Medicare beneficiaries face near-universal prior authorization for GLP-1 drugs.
5. NovoCare. Wegovy pricing and savings programs.
6. LillyDirect. Zepbound vial pricing. Updated February 2026.